Add listing
    0
    Add listing

    Amporin Pharmaceuticals AG Verified listing

    • Swiss Biotech Association
      Member

    Amporin Pharmaceuticals AG is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral disease-modifying treatments for degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease and ALS.

    Location
    Canton
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2024
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in